Leuject

Cladribine, the active ingredient in Leuject, is a purine nucleoside analog presented as a sterile solution for subcutaneous administration. It selectively depletes lymphocytes by incorporating into DNA, and is indicated for the treatment of hairy cell leukemia and for disease‑modifying therapy of multiple sclerosis in adult patients.

GNH USA supplies Leuject as a licensed, Good Distribution Practice‑compliant product sourced from the European Union, providing reliable supply to hospitals, oncology centres, pharmacies and clinics worldwide while meeting all applicable regulatory standards and supporting patient care.

Cladribine is employed in the management of hematologic malignancies and neuro‑inflammatory disease.

Hairy cell leukemia: Cladribine induces durable remission by selectively incorporating into the DNA of malignant B‑lymphocytes, leading to apoptosis and depletion of the leukemic clone. Multiple sclerosis: The drug acts as an immunomodulatory agent that reduces the frequency of clinical relapses and slows accumulation of disability by depleting pathogenic lymphocytes involved in central nervous system inflammation.

Cladribine may cause a range of adverse reactions.

Common Side Effects: - Injection site pain or erythema - Nausea or vomiting - Fatigue or general weakness - Transient fever or flu‑like symptoms - Mild lymphopenia - Headache

Serious or Rare Side Effects: - Severe or opportunistic infections - Profound lymphopenia increasing infection risk - Autoimmune hepatitis or liver dysfunction - Secondary malignancies - Anaphylactic reactions - Severe cutaneous adverse reactions (e.g., Stevens‑Johnson syndrome)

Patients receiving Cladribine should be monitored closely for safety.

Monitor blood counts: regular CBC to detect lymphopenia. Assess infection risk: screen for active infections before initiation. Evaluate organ function: check renal and hepatic parameters. Avoid use in pregnancy: only if benefits outweigh risks. Discontinue if severe infection occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine may interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Live attenuated vaccines: risk of uncontrolled infection. - Concurrent cytotoxic chemotherapy: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Strong immunosuppressants (e.g., azathioprine): may enhance lymphocyte depletion. - Antifungal agents metabolized by CYP enzymes: potential altered drug levels. - NSAIDs: may increase risk of gastrointestinal irritation.